Hostname: page-component-7c8c6479df-fqc5m Total loading time: 0 Render date: 2024-03-28T05:17:26.779Z Has data issue: false hasContentIssue false

Homocysteine increases the risk of mortality in elderly individuals

Published online by Cambridge University Press:  01 June 2007

Sonia González
Affiliation:
Departamento de Biología Funcional, Área de Fisiología, Facultad de Medicina, Universidad de Oviedo, Julián Clavería s/n, 33006, Oviedo, Spain
José M. Huerta
Affiliation:
Departamento de Biología Funcional, Área de Fisiología, Facultad de Medicina, Universidad de Oviedo, Julián Clavería s/n, 33006, Oviedo, Spain
Serafina Fernández
Affiliation:
Departamento de Biología Funcional, Área de Fisiología, Facultad de Medicina, Universidad de Oviedo, Julián Clavería s/n, 33006, Oviedo, Spain
Ángeles M. Patterson
Affiliation:
Departamento de Biología Funcional, Área de Fisiología, Facultad de Medicina, Universidad de Oviedo, Julián Clavería s/n, 33006, Oviedo, Spain
Cristina Lasheras*
Affiliation:
Departamento de Biología Funcional, Área de Fisiología, Facultad de Medicina, Universidad de Oviedo, Julián Clavería s/n, 33006, Oviedo, Spain
*
*Corresponding author: Dr Cristina Lasheras, fax +34 98 5103534, email lasheras@uniovi.es
Rights & Permissions [Opens in a new window]

Abstract

Although total plasma homocysteine (tHcy) has been extensively studied as a risk factor of CVD, longitudinal evidence on its association with mortality is scarce, especially among the elderly. The study cohort consisted of 215 subjects (eighty-eight male and 127 female), aged 60 years or older, recruited in fourteen elderly care institutions from Asturias (Spain). All participants were free of major chronic pathology and took no vitamin and/or mineral supplements. Baseline determinations included tHcy in plasma and folate, vitamin B12 and Se in serum. Survival analyses were performed by quintiles of these factors after 6 years (mean follow-up time 4·3 years) by means of Cox regression models. During follow-up time sixty participants died. tHcy above 16·7 μmol/l was associated with an increased risk of mortality in the sample (relative risk 2·30 (95 % CI 1·02, 5·17)). Among the nutritional determinants of tHcy evaluated, folate and Se were not predictive of death risk of the cohort, while vitamin B12 showed inconsistent results. Nevertheless, mortality was significantly lower at higher serum Se levels (upper quintile), but this effect was restricted to women. Higher tHcy in both sexes and lower serum Se in women were found to be independently associated with an increased risk of death in elderly subjects.

Type
Full Papers
Copyright
Copyright © The Authors 2007

Homocysteine is a sulfur-containing amino acid playing a key role in methionine metabolism (Finkelstein, Reference Finkelstein1990) that has been described to be a useful biological marker of disease. In the last two decades, many retrospective and cross-sectional studies have consistently linked premature vascular disorders and CVD with higher total plasma homocysteine (tHcy) levels (Graham et al. Reference Graham, Daly and Refsum1997; Hankey & Eikelboom, Reference Hankey and Eikelboom1999; Homocysteine Studies Collaboration, 2002). Prospective investigations have also found that cardiovascular risk rises with increasing tHcy in a dose-dependent manner (Boushey et al. Reference Boushey, Beresford, Omenn and Motulsky1995; Perry et al. Reference Perry, Refsum, Morris, Ebrahim, Ueland and Shaper1995), while subjects with lower tHcy levels also show reduced risk of stroke and IHD (Homocysteine Studies Collaboration, 2002). Nevertheless, recent randomised clinical trials designed to lower tHcy concentrations have proven ineffective in preventing cardiovascular events (Bonaa et al. Reference Bonaa, Njolstad, Ueland, Schirmer, Tverdal, Steigen, Wang, Nordrehaug, Arnesen and Rasmussen2006; Lonn et al. Reference Lonn, Yusuf, Arnold, Sheridan, Pogue, Micks, McQueen, Probstfield, Fodor, Held and Genest2006), so that controversy still exists. In addition to its role on cardiovascular morbidity, recent research has suggested that tHcy might also be implicated in several other age-related pathologies, such as Alzheimer's disease, dementia (Clarke et al. Reference Clarke, Smith, Jobst, Refsum, Sutton and Ueland1998; Morris, Reference Morris2003) and osteoporosis (Verhoef & de Groot, Reference Verhoef and de Groot2005), although the mechanisms underlying these associations have not yet been elucidated.

In agreement with its well-documented association with chronic disease, studies carried out to analyse whether plasma homocysteine would be predictive of mortality in human subjects show consistent results. Several authors have found supporting evidence for this association in patient populations with renal failure (Buccianti et al. Reference Buccianti, Baragetti, Bamonti, Furiani, Dorighet and Patrosso2004), CVD (Nygard et al. Reference Nygard, Nordrehaug, Refsum, Ueland, Farstad and Vollset1997; Anderson et al. Reference Anderson, Muhlestein, Horne, Carlquist, Bair, Madsen and Pearson2000; Omland et al. Reference Omland, Samuelsson, Hartford, Herlitz, Karlsson, Christensen and Caidahl2000; Rossi et al. Reference Rossi, Maiolino, Seccia, Burlina, Zavattiero, Cesari, Sticchi, Pedon, Zanchetta and Pessina2006) and diabetes (Stehouwer et al. Reference Stehouwer, Gall, Hougaard, Jakobs and Parving1999). It should be pointed out, nevertheless, that all these subjects in whom tHcy has been found to predict fatal outcomes were already at higher risk of overall mortality because of their underlying pathological conditions. Although some authors have reported an association of tHcy with mortality in non-risk populations (Bostom et al. Reference Bostom, Silbershatz, Rosenberg, Selhub, D'Agostino, Wolf, Jacques and Wilson1999; Kark et al. Reference Kark, Selhub, Adler, Gofin, Abramson, Friedman and Rosenberg1999; Vollset et al. Reference Vollset, Refsum, Tverdal, Nygard, Nordrehaug, Tell and Ueland2001), at least one study has failed to find tHcy associated with cardiovascular mortality (de Bree et al. Reference de Bree, Verschuren, Blom, Nadeau, Trijbels and Kromhout2003). Still, epidemiological data on this topic are scarce, especially among the elderly.

Hyperhomocysteinaemia is determined by genetic, environmental and nutritional factors (Selhub, Reference Selhub1999; Jacques et al. Reference Jacques, Bostom, Wilson, Rich, Rosenberg and Selhub2001; Saw et al. Reference Saw, Yuan, Ong, Arakawa, Lee, Coetzee and Yu2001). Folate, vitamin B12, vitamin B6 and riboflavin are the most studied nutritional determinants of plasma tHcy concentrations (Selhub et al. Reference Selhub, Jacques, Wilson, Rush and Rosenberg1993; Brouwer et al. Reference Brouwer, Verhoef and Urgert2000; Jacques et al. Reference Jacques, Kalmbach, Bagley, Russo, Rogers, Wilson, Rosenberg and Selhub2002); however, a recent study carried out by our group has also found Se to be a strong and independent determinant of the levels of this amino acid (González et al. Reference González, Huerta, Álvarez-Uría, Fernández, Patterson and Lasheras2004). The significant association of all these factors with plasma homocysteine concentrations allows us to conceive a potential role for them in preventing tHcy-related pathologies and, eventually, mortality.

The present longitudinal study has been conducted to analyse the prospective association of homocysteine, and several nutrition-related factors, on survival time in elderly subjects from the North of Spain who were followed up for a maximum of 6 years.

Subjects and methods

Study sample, setting and recruitment

A total sample of 304 subjects (age 60 years old and over) was recruited in Asturias (Northern Spain) between 1999 and 2002, in fourteen public and private care institutions for elderly individuals. The recruitment of the sample comprised two phases. Phase 1 took place between 1999 and 2000 and included 184 elderly subjects from seven elderly care institutions. In phase 2 (year 2002), the previous sample was enlarged with 120 new participants from seven other different institutions.

A medical history of each subject was obtained before enrolment. Subjects were required to be mentally and physically able to take part in the study. On this basis, elderly residents with a previous history of cancer, mental impairment or CVD were not included, and neither were those confined to a wheelchair or suffering from a terminal disease. A total of eighty-nine subjects were excluded from the analyses due to missing values in biochemical parameters (n 38), regular consumption of vitamin and/or mineral supplements (n 4) or following a special diet (n 47). The final sample comprised 215 subjects, eighty-eight men and 127 women, with a mean age of 73·4 (sd 7·3) and 76·3 (sd 5·7) years, respectively.

The study design was approved by the Committee on Ethical Research of the Asturias Central University Hospital. All participants were informed of the objectives and methodology of the study and gave written consent.

Data collection

The longitudinal analysis presented in the present paper is part of a broader epidemiological study on diet, biological markers of disease and mortality. As part of the dietary approach, variables concerning energy, and macro- and micronutrient intake were recorded, by trained dietitians, by means of a FFQ specific for each of the fourteen institutions. Methodological details in regard to dietary assessment have been presented elsewhere (Lasheras et al. Reference Lasheras, González, Huerta, Lombardía, Ibáñez, Patterson and Fernández2003).

During the personal interview information was also collected on potential confounders such as smoking habit (yes, no), and cognitive status, measured by means of the Lobo test, an adaptation of the Mini Mental State Examination for the Spanish population (Lobo et al. Reference Lobo, Saz, Marco, Bulbena, Berrios and Fernández de Larrinoa2005). A medical history was obtained for each participant, and consumption of drugs was registered.

Height (in m) of the participants was measured using a stadiometer exact to 1 mm (Año-Sayol, Barcelona, Spain), with subjects barefoot and positioned in the Frankfort plane. Weight (in kg) was registered to the nearest 500 g with a precision scale (Seca, Hamburg, Germany). BMI of the participants was then calculated as weight divided by height squared (kg/m2).

Blood sample pre-treatment and biochemical analyses

A total of 30 ml of whole blood were drawn from each participant by venepuncture after a 12 h fast, and collected in separated tubes for serum and plasma. Samples were kept cold in the dark until processed in the laboratory. To obtain plasma samples, heparin-treated tubes were centrifuged at 1000 g for 15 min at room temperature within the following 2–4 h after the collection. Blood collected into non-heparinised tubes was allowed to clot in the dark at room temperature for 4 h before centrifugation, and serum removed. Plasma and serum samples of 500 μl were stored frozen at − 70°C until analyses were performed.

tHcy was determined using reverse-phase HPLC with fluorimetric detection (Araki & Sako, Reference Araki and Sako1987) on Bio-Rad equipment (Bio-Rad, Richmond, CA, USA). To assure the stability of the analytical procedure, cysteine and cysteineglycine (two aminothiols) were measured together with homocysteine in the same sample and their concentrations (absolute and relative to homocysteine) were checked to be within the reference range. CV for tHcy determination was 8 %. Serum folate and vitamin B12 concentrations were determined using a competitive-binding immunoenzymic assay on an Access® automated immunoassay analyser from Beckman (Chaska, MN, USA). Imprecision (as the CV) was 15 % for folate and 7 % for vitamin B12. Se was analysed in serum by graphite-furnace flame atomic absorption spectrometry (Jacobson & Lockitch, Reference Jacobson and Lockitch1988). Seronorm Trace Elements Serum standard (SERO AS, Billingstad, Norway) was used as quality control. CV for Se determination was 10 %. Serum creatinine was measured in a Hitachi 737 analyser (Boehringer Mannheim Corp., Indianapolis, IN, USA) by the modified kinetic Jaffé reaction (Kasiske & Keane, Reference Kasiske, Keane, Brenner and Rector1996).

Biochemical analyses were performed at the Laboratory of Clinical Analysis of Asturias Central Hospital (Oviedo, Spain).

Statistical analyses

Goodness of fit to normal distribution of continuous variables was analysed with the Kolmogorov–Smirnov test. Student's t tests were used to check for differences by vital status of the study sample. When distributions were skewed, a log-transformation was applied and differences analysed by means of the non-parametrical Mann–Whitney U test. For categorical variables, χ2 tests were performed to check for differences in the percentage of subjects across groups.

Cox proportional hazards models were built in order to estimate the relative risk of death by quintiles of predicting variables. The lowest quintile was defined as the reference category in each model. Multivariate adjustment included sex, age, BMI, cognitive test score and smoking habit (0 =  no; 1 =  yes). Tests for trend across quintiles were performed by entering the categorised variables as continuous.

All analyses were performed with SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, USA). Differences were considered significant at the P < 0·05 level.

Follow-up protocol

Date of entry to the study was set at the date of the personal interview (October 1999 to July 2000 in phase 1 and May 2002 to December 2002 in phase 2). Every following year, the institutions were contacted in order to assess changes in vital status of participants and to register the exact date and probable cause of every death event that had occurred. Extensive efforts were made to contact the participants who had moved out from any institution, requesting the new address if possible. When this information was not available, the case was registered as a loss to follow-up, and survival time censored at the date when the participant had left the centre. Less than 4·3 % of subjects (n 11) were lost to follow-up during the study period. Closing date for survival analyses was considered that of the last contact with each centre (January to February 2006). A total number of sixty death cases (28 %) were registered and, according to information provided, none died of accident or committed suicide. Mean survival time for the whole cohort was 1556 d.

Results

Baseline characteristics of the study sample are presented in Table 1 for the whole cohort and separately for sex and vital status. Mean age at enrolment was higher in women than in men. The percentage of actual smokers was lower in women, who also showed higher basal serum folate and poorer cognitive performance. Those who died showed significantly higher tHcy and lower serum Se concentrations at enrolment than survivors, but no differences were found for folate or vitamin B12 between both groups. Those subjects who died also had a lower BMI at the time of recruitment (probably a consequence of the different sex ratio between groups and the difference in BMI between men and women).

Table 1 Baseline characteristics of the sample according to vital status (Mean values and standard deviations, or percentage of subjects)

* Mean value or percentage was significantly different from that of the men (P < 0·05).

Mean value was significantly different from that of the survivors (P < 0·05).

Mini Mental State Examination score (adapted by Lobo et al. (Reference Lobo, Saz, Marco, Bulbena, Berrios and Fernández de Larrinoa2005) for the Spanish population).

The results of Cox proportional hazards regression models for categories of studied variables are shown in Table 2. Quintiles of blood homocysteine, folate, vitamin B12 and Se were calculated and introduced as predicting variables in multivariate Cox models, controlling for several potential confounders. A 2·3-fold higher risk of death was found for subjects in the upper quintile of tHcy distribution as compared with those in the lowest one (reference category). Serum folate and Se levels were not significantly associated with survival time in the sample. Quintiles of vitamin B12 were not associated with overall mortality, but a significant trend in mortality with increasing B12 levels in the fully adjusted model was observed.

Table 2 Estimates of risk derived from Cox proportional hazards models for plasma homocysteine, folate, vitamin B12 and selenium as predictors of survival time (Relative risks (RR) and 95 % confidence intervals)

* Increased risk of death was significant (P < 0·05).

Adjusted for age and sex.

Adjusted for age, sex, smoking habit, BMI and cognitive score.

Discussion

The major outcome of the present study is the association between tHcy and Se with risk of overall mortality in a non-risk elderly population. Although multiple evidence supports tHcy as a marker of several pathological conditions, its association with mortality remains insufficiently documented in the general population.

We report a 2·3-fold higher chance of all-cause death in subjects with higher tHcy levels ( ≥  16·7 μmol/l), a result which is consistent with the 2·2-fold increase in total mortality risk found by Bostom et al. (Reference Bostom, Silbershatz, Rosenberg, Selhub, D'Agostino, Wolf, Jacques and Wilson1999) for elderly of the Framingham cohort with tHcy above 14·3 μmol/l. tHcy has been reported to predict mortality in patients with renal failure or CVD. Its levels increase as a consequence of a diminished renal function; also, tHcy concentrations are known to be elevated for some time after a cardiovascular event, for up to 6 months after a myocardial infarction and for more than 1 year after a stroke (Lindgren et al. Reference Lindgren, Brattstrom, Norrving, Hultberg, Andersson and Johansson1995; Egerton et al. Reference Egerton, Silberberg, Crooks, Ray, Xie and Dudman1996). Nevertheless, the study of homocysteine in the context of chronic disease might not be an entirely valid approach to establish its potential role as an independent risk factor of mortality. In this sense, it is of importance our reporting of an increased chance of death associated with higher tHcy levels in elderly subjects free of major chronic pathologies. Although limited statistical power in the present study has probably hampered our ability to find a statistically significant graded effect on mortality (see Table 2), it should be noted that the percentage of cases significantly increased across quintiles of tHcy (P = 0·027). Still more research is necessary to precisely quantify the magnitude of the contribution of homocysteine to risk of death in the general population by strata of relevant biological, social and pathological variables.

Survival analyses were also performed for major nutritional determinants of tHcy. Folate and vitamin B12 are cooperative cofactors in homocysteine re-methylation to methionine (Selhub et al. Reference Selhub, Jacques, Wilson, Rush and Rosenberg1993; Jacques et al. Reference Jacques, Bostom, Wilson, Rich, Rosenberg and Selhub2001; Quinlivan et al. Reference Quinlivan, McPartlin, McNulty, Ward, Strain, Weir and Scott2002; Huerta et al. Reference Huerta, González, Vigil, Prada, San Martín, Fernández, Patterson and Lasheras2004), whereas serum Se concentrations strongly predict tHcy levels by yet unknown mechanisms (González et al. Reference González, Huerta, Álvarez-Uría, Fernández, Patterson and Lasheras2004). We found that higher folate or vitamin B12 levels were not associated with survival time of the cohort, in spite of our previous finding of a strong, inverse linear association between blood folate and tHcy concentrations (Huerta et al. Reference Huerta, González, Vigil, Prada, San Martín, Fernández, Patterson and Lasheras2004). Therefore, albeit important in diminishing tHcy levels, probably folate would not be effective by itself to a sufficient extent as to achieve low enough tHcy concentrations to prevent overall mortality in the cohort. Regarding vitamin B12 levels, while it is common that elderly subjects could be at risk of cobalamin deficiency, less than 15 % of subjects in our cohort had suboptimal serum concentrations (below 185 pmol/l) (Selhub et al. Reference Selhub, Jacques, Rosenberg, Rogers, Bowman, Gunter, Wright and Johnson1999). Because of these high levels of vitamin B12 we were unable to find a linear association between serum cobalamin and tHcy in a previous report (Huerta et al. Reference Huerta, González, Vigil, Prada, San Martín, Fernández, Patterson and Lasheras2004). The present results are not conclusive in regard to the association of cobalamin with survival time. While we found a significant direct trend, the categorical analysis did not support an association between cobalamin and overall survival. Further research is required to help clarify this topic.

Our group has recently found that Se is inversely associated with tHcy in human subjects (González et al. Reference González, Huerta, Álvarez-Uría, Fernández, Patterson and Lasheras2004), but the present results do not clearly support an overall protective effect in regard to mortality. In the present study, the percentage of deaths did not significantly differ across quintiles of serum Se. Se did not significantly predict survival time in Cox models, either. Although it is generally assumed that a poor Se status has an adverse impact on health maintenance and proper function of body systems (Rayman, Reference Rayman2000), epidemiological evidence on the role of Se on survival remain inconclusive. Cardiovascular mortality was not affected by Se status in case–control studies or after long-term supplementation (Salonen et al. Reference Salonen, Salonen, Penttila, Herranen, Jauhiainen, Kantola, Lappetelainen, Maenpaa, Alfthan and Puska1985; Kok et al. Reference Kok, de Bruijn, Vermeeren, Hofman, van Laar, de Bruin, Hermus and Valkenburg1987b; Stranges et al. Reference Stranges, Marshall, Trevisan, Natarajan, Donahue, Combs, Farinaro, Clark and Reid2006), except for those with low basal Se status (Salonen et al. Reference Salonen, Alfthan, Huttunen, Pikkarainen and Puska1982). On the other hand, previous evidence showed that cancer-related mortality was higher in elderly subjects with lower basal Se concentrations (Akbaraly et al. Reference Akbaraly, Arnaud, Hininger-Favier, Gourlet, Roussel and Berr2005) and that daily supplementation with 200 μg Se reduced cancer incidence and mortality in adult populations (Kok et al. Reference Kok, de Bruijn, Hofman, Vermeeren and Valkenburg1987a; Duffield-Lillico et al. Reference Duffield-Lillico, Reid, Turnbull, Combs, Slate, Fischbach, Marshall and Clark2002), but the effect generally seems to be restricted to men and to subjects in the lowest categories of basal Se levels (although the consideration of ‘low Se level’ largely differs among these studies). This sex-specific effect led us to check for potential differences in total mortality risk by sex across levels of serum Se. We found that women, but not men, in the highest quintile of serum Se distribution had up to 83 % lower chance of overall death (women: odds ratio 0·168 (95 % CI 0·032, 0·873), P = 0·034; men: odds ratio 0·978 (95 % CI 0·310, 3·083), P = 0·970; data not shown). This association persisted after including tHcy as a predictor in the adjusted model, which suggests that the protective effect of Se would not entirely rely on its association with homocysteine. Se has many other important functions: it is a cofactor of glutathione peroxidase protecting against harmful peroxidation (Heyland et al. Reference Heyland, Dhaliwal, Suchner and Berger2005); it modulates the response to oxidative stress by inducing a faster restoration of the endogenous antioxidant defence system (Savarino et al. Reference Savarino, Granchi, Ciapetti, Cenni, Ravaglia, Forti, Maioli and Mattioli2001); besides, Se plays an important role in immunity, thyroid function and inflammatory processes, among other actions, that would partly account for its direct association with survival time in human subjects (Rayman, Reference Rayman2000). The fact that this effect has been found to be restricted to either men or women, depending on the study, raises the question of whether there exist unknown sex-related factors underlying the association of serum Se with mortality.

In interpreting these results, some considerations should be borne in mind. The study suffers from a low sample size that may have resulted in a reduced statistical power. But, on the other hand, the finding of significant differences in spite of this limited statistical power allows us to feel confident about the results that we did find. Because of the low number of subjects and, subsequently, of deaths (sixty cases), further larger population-based studies should estimate the magnitude of these associations with greater accuracy. Also, the present study has been carried out in an institutionalised population, and it is not clear to what extent these results can be generalised to free-living elderly. Finally, a longer follow-up period will show whether tHcy also predicts survival time on a long-term basis.

To our knowledge, the present study is the first prospective epidemiological study in the literature that examines the association on survival time of blood levels of homocysteine, folate, cobalamin and Se together, in non-patient elderly not receiving micronutrient supplementation. According to our data, physiological concentrations of tHcy were predictive of risk of overall mortality, while folate and vitamin B12 levels were not. Higher serum Se showed a beneficial effect, although only in women. The role of tHcy in predicting risk of death merits further research efforts.

Acknowledgements

We thank the staff of the elderly care institutions for their participation in the present study. The present study was supported by a grant from ERA (Establecimientos Residenciales para Ancianos Asturianos), a grant FIS-02-PI020141 from the Spanish Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III, Madrid, Spain), and a Grande Covián grant from the Prince of Asturias Foundation (Oviedo, Spain).

References

Akbaraly, NT, Arnaud, J, Hininger-Favier, I, Gourlet, V, Roussel, AM & Berr, C (2005) Selenium and mortality in the elderly: Results from the EVA Study. Clin Chem 51, 21172123.CrossRefGoogle ScholarPubMed
Anderson, JL, Muhlestein, JB, Horne, BD, Carlquist, JF, Bair, TL, Madsen, TE & Pearson, RR (2000) Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 102, 12271232.CrossRefGoogle ScholarPubMed
Araki, A & Sako, Y (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422, 4352.CrossRefGoogle ScholarPubMed
Bonaa, KH, Njolstad, I, Ueland, PM, Schirmer, H, Tverdal, A, Steigen, T, Wang, H, Nordrehaug, JE, Arnesen, E & Rasmussen, K (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 15781588.Google Scholar
Bostom, AG, Silbershatz, H, Rosenberg, IH, Selhub, J, D'Agostino, RB, Wolf, PA, Jacques, PF & Wilson, PW (1999) Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 159, 10771080.CrossRefGoogle ScholarPubMed
Boushey, CJ, Beresford, SA, Omenn, GS & Motulsky, AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 10491057.Google Scholar
Brouwer, IA, Verhoef, P & Urgert, R (2000) Betaine supplementation and plasma homocysteine in healthy volunteers. Arch Intern Med 160, 25462547.CrossRefGoogle ScholarPubMed
Buccianti, G, Baragetti, I, Bamonti, F, Furiani, S, Dorighet, V & Patrosso, C (2004) Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 17, 405410.Google Scholar
Clarke, R, Smith, AD, Jobst, KA, Refsum, H, Sutton, L & Ueland, PM (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55, 14491455.Google Scholar
de Bree, A, Verschuren, WM, Blom, HJ, Nadeau, M, Trijbels, FJ & Kromhout, D (2003) Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis 166, 369377.Google Scholar
Duffield-Lillico, AJ, Reid, ME, Turnbull, BW, Combs, GF Jr, Slate, EH, Fischbach, LA, Marshall, JR & Clark, LC (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11, 630639.Google Scholar
Egerton, W, Silberberg, J, Crooks, R, Ray, C, Xie, L & Dudman, N (1996) Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 77, 759761.Google Scholar
Finkelstein, JD (1990) Methionine metabolism in mammals. J Nutr Biochem 1, 228237.Google Scholar
González, S, Huerta, JM, Álvarez-Uría, J, Fernández, S, Patterson, AM & Lasheras, C (2004) Serum selenium is associated with plasma homocysteine concentrations in elderly humans. J Nutr 134, 17361740.Google Scholar
Graham, IM, Daly, LE, Refsum, HM, et al. (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277, 17751781.Google Scholar
Hankey, GJ & Eikelboom, JW (1999) Homocysteine and vascular disease. Lancet 354, 407413.Google Scholar
Heyland, DK, Dhaliwal, R, Suchner, U & Berger, MM (2005) Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Med 31, 327337.Google Scholar
Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 20152022.Google Scholar
Huerta, JM, González, S, Vigil, E, Prada, M, San Martín, J, Fernández, S, Patterson, AM & Lasheras, C (2004) Folate and cobalamin synergistically decrease the risk of high plasma homocysteine in a nonsupplemented elderly institutionalized population. Clin Biochem 37, 904910.CrossRefGoogle Scholar
Jacobson, BE & Lockitch, G (1988) Direct determination of selenium in serum by graphite-furnace atomic absorption spectrometry with deuterium background correction and a reduced palladium modifier: age-specific reference ranges. Clin Chem 34, 709714.CrossRefGoogle Scholar
Jacques, PF, Bostom, AG, Wilson, PW, Rich, S, Rosenberg, IH & Selhub, J (2001) Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 73, 613621.Google Scholar
Jacques, PF, Kalmbach, R, Bagley, PJ, Russo, GT, Rogers, G, Wilson, PW, Rosenberg, IH & Selhub, J (2002) The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 132, 283288.CrossRefGoogle ScholarPubMed
Kark, JD, Selhub, J, Adler, B, Gofin, J, Abramson, JH, Friedman, G & Rosenberg, IH (1999) Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 131, 321330.Google Scholar
Kasiske, BL & Keane, WF (1996) Laboratory assessment of renal disease clearance, urinalysis and renal biopsy. In The Kidney, pp. 11371173 [Brenner, BM and Rector, FC Jr, editors]. Philadelphia: WB Saunders.Google Scholar
Kok, FJ, de Bruijn, AM, Hofman, A, Vermeeren, R & Valkenburg, HA (1987 a\) Is serum selenium a risk factor for cancer in men only? Am J Epidemiol 125, 1216.Google Scholar
Kok, FJ, de Bruijn, AM, Vermeeren, R, Hofman, A, van Laar, A, de Bruin, M, Hermus, RJ & Valkenburg, HA (1987 b\) Serum selenium, vitamin antioxidants, and cardiovascular mortality: a 9-year follow-up study in the Netherlands. Am J Clin Nutr 45, 462468.CrossRefGoogle ScholarPubMed
Lasheras, C, González, S, Huerta, JM, Lombardía, C, Ibáñez, R, Patterson, AM & Fernández, S (2003) Food habits are associated with lipid peroxidation in an elderly population. J Am Diet Assoc 103, 14801487.Google Scholar
Lindgren, A, Brattstrom, L, Norrving, B, Hultberg, B, Andersson, A & Johansson, BB (1995) Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 26, 795800.CrossRefGoogle ScholarPubMed
Lobo, A, Saz, P & Marco, C (2005) Demencias. In Medición Clínica en Psiquiatría y Psicología, pp. 335347 [Bulbena, A, Berrios, GE and Fernández de Larrinoa, P, editors]. Barcelona: Masson.Google Scholar
Lonn, E, Yusuf, S, Arnold, MJ, Sheridan, P, Pogue, J, Micks, M, McQueen, MJ, Probstfield, J, Fodor, G, Held, C & Genest, J Jr (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 15671577.Google Scholar
Morris, MS (2003) Homocysteine and Alzheimer's disease. Lancet Neurol 2, 425428.CrossRefGoogle ScholarPubMed
Nygard, O, Nordrehaug, JE, Refsum, H, Ueland, PM, Farstad, M & Vollset, SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337, 230236.CrossRefGoogle ScholarPubMed
Omland, T, Samuelsson, A, Hartford, M, Herlitz, J, Karlsson, T, Christensen, B & Caidahl, K (2000) Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch Intern Med 160, 18341840.CrossRefGoogle ScholarPubMed
Perry, IJ, Refsum, H, Morris, RW, Ebrahim, SB, Ueland, PM & Shaper, AG (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346, 13951398.Google Scholar
Quinlivan, EP, McPartlin, J, McNulty, H, Ward, M, Strain, JJ, Weir, DG & Scott, JM (2002) Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 359, 227228.Google Scholar
Rayman, MP (2000) The importance of selenium to human health. Lancet 356, 233241.CrossRefGoogle ScholarPubMed
Rossi, GP, Maiolino, G, Seccia, TM, Burlina, A, Zavattiero, S, Cesari, M, Sticchi, D, Pedon, L, Zanchetta, M & Pessina, AC (2006) Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. J Hypertens 24, 851859.Google Scholar
Salonen, JT, Alfthan, G, Huttunen, JK, Pikkarainen, J & Puska, P (1982) Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet ii, 175179.CrossRefGoogle Scholar
Salonen, JT, Salonen, R, Penttila, I, Herranen, J, Jauhiainen, M, Kantola, M, Lappetelainen, R, Maenpaa, PH, Alfthan, G & Puska, P (1985) Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 56, 226231.Google Scholar
Savarino, L, Granchi, D, Ciapetti, G, Cenni, E, Ravaglia, G, Forti, P, Maioli, F & Mattioli, R (2001) Serum concentrations of zinc and selenium in elderly people: results in healthy nonagenarians/centenarians. Exp Gerontol 36, 327339.Google Scholar
Saw, SM, Yuan, JM, Ong, CN, Arakawa, K, Lee, HP, Coetzee, GA & Yu, MC (2001) Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr 73, 232239.CrossRefGoogle ScholarPubMed
Selhub, J (1999) Homocysteine metabolism. Annu Rev Nutr 19, 217246.Google Scholar
Selhub, J, Jacques, PF, Rosenberg, IH, Rogers, G, Bowman, BA, Gunter, EW, Wright, JD & Johnson, CL (1999) Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991–1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 131, 331339.Google Scholar
Selhub, J, Jacques, PF, Wilson, PW, Rush, D & Rosenberg, IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270, 26932698.CrossRefGoogle Scholar
Stehouwer, CD, Gall, MA, Hougaard, P, Jakobs, C & Parving, HH (1999) Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 55, 308314.CrossRefGoogle ScholarPubMed
Stranges, S, Marshall, JR, Trevisan, M, Natarajan, R, Donahue, RP, Combs, GF, Farinaro, E, Clark, LC & Reid, ME (2006) Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. Am J Epidemiol 163, 694699.CrossRefGoogle ScholarPubMed
Verhoef, P & de Groot, LC (2005) Dietary determinants of plasma homocysteine concentrations. Semin Vasc Med 5, 110123.CrossRefGoogle ScholarPubMed
Vollset, SE, Refsum, H, Tverdal, A, Nygard, O, Nordrehaug, JE, Tell, GS & Ueland, PM (2001) Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 74, 130136.Google Scholar
Figure 0

Table 1 Baseline characteristics of the sample according to vital status (Mean values and standard deviations, or percentage of subjects)

Figure 1

Table 2 Estimates of risk derived from Cox proportional hazards models for plasma homocysteine, folate, vitamin B12 and selenium as predictors of survival time (Relative risks (RR) and 95 % confidence intervals)